Key Takeaways
- Record revenue, burdened profitability: Revenue hit a record ₹614 crores, yet macro pressures, energy costs, and a lag in cost pass-through compressed margins across all segments.
- Carbogen Amcis CRAMS margin halved: Margins fell from ~21% to 14.6% YoY, driven by a 2x increase in energy costs and a revenue mix skewed toward early-phase development work.
- India margins depressed but poised: India API and intermediates posted a positive EBITDA margin of ~6.5%, weighed down by underutilization at Bavla; management targets a return to 20–25% margins next year on a 25% revenue increase.
- EDQM reinspection clock is ticking: The company has completed its dialogue with EDQM and requested reinspection in October; the standard six-month window sets April as the outer deadline for a resolution.
- What to watch next quarter: Whether the cost pass-through to customers materializes to lift margins, the pace of EDQM reinspection progress, and any recovery in cholesterol demand as customer stock levels normalize.
Segment Performance
- Carbogen Amcis CRAMS: Revenue grew 39% to ₹438 crores, described as phenomenal performance, but EBITDA margin fell sharply from ~21% to 14.6% YoY. The margin compression was driven by energy costs increasing close to 2x and a revenue mix dominated by early-phase development work rather than higher-margin commercial or Phase III work.
- India NCE APIs and intermediates: Revenue grew 62%, driven by increased shipments from the Bavla site and the appearance of many customers from the previous year. EBITDA margin was positive at about 6.5% in Q2 and 5% in H1, depressed by underutilization at Bavla and an increased cost base.
- India Quats and Generics: Revenue grew 44% to ₹48 crores, described as phenomenal performance.
- Netherlands: Suffered the highest margin dip in the business, from 30% in H1 FY22 to 18.7% in H1 FY23, largely on account of a sustained increase in bulkers prices. The company is attempting to pass on as much of the increase as possible on the analogues side, a more profitable business.
- Cholesterol: Demand declined because cholesterol is a major raw material for vitamin D3, which saw higher demand during COVID. Customers are now sitting on high stock levels because they anticipated a consumption slowdown, creating an offset on demand. Recovery is expected once customer stock levels normalize.
Pascal Villemagne: "So unfortunately, what we are implementing right now in terms of digital transformation and all the initiatives that we are taking will probably help us to improve a little bit the situation where we are in. But it would be difficult to reach the 90% as targeted for this year due to all those external circumstances."
Margins & Cost Structure
- Cost pass-through lag: An increase in the cost base, especially fixed costs, negatively impacted EBITDA margins. There is a time lag between cost increases and passing them on to customers, with a shift in margins expected in coming quarters.
- Finance cost increase: Finance costs rose due to globally announced interest rate increases affecting LIBOR costs in each foreign currency, plus a forex impact of about ₹1.5 crores.
- Forex impact comparison: Q2 FY23 EBITDA included a forex gain of ₹5.6 crores versus a ₹45 crore gain in Q2 FY22, which had a large amount of hedging gains booked.
- India fixed cost coverage: At Naroda, all fixed costs are now getting covered by existing sales; incremental sales should result in addition to EBITDA because no major capex has been done and no major additional expenses are expected.
- EDQM-related costs: Extraordinary costs incurred for EDQM audit preparation and broader facility improvements are not expected to recur starting next financial year, which should help improve operating margins.
- Carbogen Amcis margin target: Management stated it would be difficult to reach the 30% margin target for this year due to external circumstances including energy costs, supplier uncertainties, and raw material costs, although digital transformation and other initiatives will probably help improve the situation a little bit.
Arpit Vyas: "It may be evident on the results that macro global uncertainties that our world face has burdened the economy. That, even after having one of the best quarters for revenue, this burden on the global economy has inevitably burdened our profitability as well."
EDQM & Facility Upgrades
- Reinspection timeline: The company requested reinspection on 18th October; EDQM accepted the request and subsequently asked for technicalities, to which the company responded on 10th November. The discussion between the company and EDQM is now complete, with all required information provided. Standard practice allows six months for EDQM to come and reinspect the Bavla facility, making April the outer deadline.
- CAPA remediation progress: More than 97% of original CAPA activities have been completed; remaining long-term CAPAs are to be completed in coming months and are not strictly related to the original CAPA.
- Bavla site improvements: As part of the remediation plan, the company rebuilt a new PC lab using a German supplier, is rebuilding a new purifying water plant with a Swiss supplier, rebuilt all material management including warehouses, added technology including lab biosafety cabinets, and is completing new stability chambers.
- Naroda facility upgrades: The company refurnished and completed the warehouse for raw material; all warehouses have been provided with access control, cameras, RLS, and sophisticated software.
Pipeline & New Capacity
- Development pipeline: The CHF 12.2 crore development product pipeline represents approximately 18 months of work for the Switzerland, UK, and China facilities, described as a "rock-solid pipeline" of new orders already enhanced.
- Commercial forecast: Commercial product volumes in Switzerland are showing a "net grade of volumes," with forecast achieving about CHF 7.5 crore versus just below CHF 7 crore previously.
- RIOM2 facility (France): The first purchase order has been booked despite the facility still being under validation and qualification. The facility is in the final phase of qualifying and validating, with production expected to start during Q1 by end of March; a few months of delay were caused by late deliveries of manufacturing lines due to COVID consequences.
- Switzerland facility extension: A very large purchase order tender was received from a major Japanese customer to cover the next campaign, starting mid-next year for commercial starting by '25, '26.
- ADC expansion: Expansion for ADC is on the verge of completion; production expected to start from next calendar year, with a substantial order already received from the customer.
Pascal Villemagne: "We booked our first purchase order despite of the fact that we are still under validation and qualification of that state-of-the-art new unit. It's extremely good news which we have this first PO in hand prior to any kind of official validation."
Digital Transformation
- Project Apollo: Globally, 90% of operations are to be put onto a single SAP platform. In the worst-case scenario, it will reduce manpower drastically; in the intended scenario, it will increase output per person dramatically.
- SAP SuccessFactors: The SAP HR management module has already gone live in India and is planned to go live in the rest of the world in January.
- LIMS implementation: LIMS for managing technical instruments is an ongoing activity currently in Switzerland, with the rest of the world soon to follow.
- SAP at Carbogen Amcis: SAP implementation is to kickstart by December 2022 with the objective to finalize by April 2024; it is expected to drastically improve efficiencies and drive profit to a higher level, helping to fight external circumstances such as raw material cost increases, energy cost increases, and inflation-driven salary increases across Europe.
- Operational excellence: Ongoing in Naroda, achieving almost 35% to 36% at EBITDA level even in tough times; same work is ongoing for Bavla and similar initiatives for the rest of the world.
Arpit Vyas: "All of this is going to eventually result into two things. In the worst-case scenario, it will reduce the manpower drastically; or in the intended scenario, it will increase the output per person dramatically."
India Business Trajectory
- Peak revenue potential: From currently operational units (7–8 in Bavla plus 2 in Naroda), peak revenue of INR 600–800 crores is achievable in the medium term; this excludes any contribution from the 4–5 currently shutdown plants.
- Revenue growth expectation: India operations revenue is expected to increase by close to about 25% next year.
- Margin trajectory: If the 25% revenue increase materializes next year, EBITDA margins should come back to around 20% to 25%; the target in the next two years' time is to return to historical 35–40% EBITDA margins. Positive EBITDA and positive profitability from India are expected from next year.
- Standalone Naroda margins: The 5% margin at Naroda in combined segment reporting also includes intermediates manufactured out of Bavla and marketing entity costs; standalone India Naroda margins would look better.
Harshil Dalal: "So what we believe is that next year, we do expect an increase in the India operations revenue by close to about 25%. And if that happens, then we should see the margins coming back to around 20% to 25% at an EBITDA level. And from there on, historically, we have done 35%, 40% margins from the India business. So that would be our target in the next two years' time."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India revenue growth | India operations revenue to increase by close to 25% | Next year (FY24) |
| India EBITDA margin | Margins to return to 20–25% if revenue growth materializes | Next year (FY24) |
| India long-term margin target | Return to historical 35–40% EBITDA margins | Next two years |
| India profitability | Positive EBITDA and positive profitability from India | Next year (FY24) |
| EDQM reinspection | EDQM to reinspect Bavla facility within standard six-month window from October intimation | By April 2023 |
| EDQM-related costs | Extraordinary costs for audit preparation and facility improvements not to recur | Starting next financial year |
| SAP implementation at Carbogen Amcis | Kickstart SAP implementation, finalize by April 2024 | December 2022 – April 2024 |
| French facility production start | Production to start at RIOM2 facility | Q1 by end of March 2023 |
| ADC expansion production start | Production to start from expanded ADC capacity | Next calendar year (2024) |
| Switzerland commercial supply | Campaign for Japanese customer to start for commercial supply | Mid-next year, commercial by '25/'26 |
| Carbogen Amcis margin target | 30% margin target difficult to reach this year due to external circumstances | FY23 (unlikely) |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹614 cr, +34% YoY vs ₹459 cr in Q2 FY22 |
| India NCE APIs & intermediates revenue growth | ~62% YoY |
| India Quats & Generics revenue | ₹48 cr, +44% YoY vs ₹33 cr in Q2 FY22 |
| Carbogen Amcis CRAMS revenue | ₹438 cr, +39% YoY vs ₹315 cr in Q2 FY22 |
| India API & intermediates EBITDA margin | ~6.5%, first half FY23 margin ~5% |
| Carbogen Amcis CRAMS EBITDA margin | 14.6%, vs close to 21% in Q2 FY22 |
| Netherlands business EBITDA margin | ~18%, first half FY23 margin ~18.7% vs 30% in H1 FY22 |
| Forex impact in EBITDA | Gain of ~₹5.6 cr, vs gain of ~₹45 cr in Q2 FY22 |
| Finance cost forex impact | ~₹1.5 cr |
| Development product pipeline | CHF 12.2 cr, covering Switzerland, UK, and China facilities |
| Commercial forecast (Switzerland) | ~CHF 7.5 cr, up from just below CHF 7 cr previously |
| India operations peak revenue potential | ₹600–800 cr in the medium term, from 10 currently operational units |
| India operations revenue growth expectation | ~25% increase next year |
| India EBITDA margin target | 20–25% next year, with 35–40% targeted in two years |
| CAPA remediation completion | >97% of original CAPA activities completed |